Pneumococcal conjugate vaccination for adults: Why it's important for children

Pediatric Infectious Disease Journal

Volumn 19, Issue 3, 2000, Pages 183-186

  Fedson, David S ^a  

^a SANOFI PASTEUR   (France)

Author keywords

Adult vaccination; Pneumococcal conjugate vaccination

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; ANTIBIOTIC RESISTANCE; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; NOTE; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS INFECTION; VACCINATION;

ADULT; AGED; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; HUMANS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 0034026740     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200003000-00002     Document Type: Note

References (30)

1. Eskola J, Antilla M. Pneumococcal conjugate vaccines. Pediatr Infect Dis J 1999;18:543-51.
2. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent conjugate pneumococcal vaccine. Pediatr Infect Dis J 2000;19:187-95.
3. Fedson DS. Pneumococcal vaccination for older adults: the first 20 years. Drugs Aging 1999; 15(Suppl 1):21-30.
4. Fedson DS. The clinical effectiveness of pneumococcal vaccination: a brief review. Vaccine 1999;17(Suppl):S85-90.
5. Ament A, Baltussen R, Duru G, et al. The cost-effectiveness of pneumococcal vaccination for older people: a study in five western European countries. Clin Infect Dis (in press).
6. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999;159:2437-42.
7. Sankilampi U, Honkanen PO, Bloigu A, Leinonen M. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1997;176:1100-4.
8. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993;270:1826-31.
9. Rubins JB, Alter M, Loch J, Janoff EN. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun 1999;67:5979-84.
10. Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999;29: 281-8.
11. Rubins JB, Puri AKG, Loch J, et al. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J Infect Dis 1998;178:431-40.
12. Usinger WR, Lucas AH. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 1999;67:2366-70.
13. Johnson SE, Rubin L, Romero-Steiner S, et al. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. J Infect Dis 1999; 180:133-40.
14. Butler JC, Cetron MS. Pneumococcal drug resistance: the new "special enemy of old age." Clin Infect Dis 1999;28: 730-5.
15. Hausdorf WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use (I). Clin Infect Dis (in press).
16. Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, Hamilton RG, Musher DM, Nelson KE. Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. J Infect Dis 1996;173:83-90.
17. 197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun 1997;65:242-7.
18. Vidarsson G, Sigurdardottir ST, Gudnason T, et al. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect Immun 1998;66:2866-70.
19. Vernacchio L, Neufeld EJ, MacDonald K, et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr 1998;133:275-8.
20. Soininen A, Seppälä I, Nieminen T, Eskola J, Käyhty H. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Vaccine 1999;17: 1889-97.
21. Chan CY, Molrine DC, George S, et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment for Hodgkin's disease. J Infect Dis 1996;173:256-8.
22. Powers DC, Anderson EL, Lottenbach K, Mink CM. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 1996;173:1014-8.
23. Ruben FL, Nagel J, Fireman P. Antitoxin responses in the elderly to tetanus-diphtheria (TD) immunization. Am J Epidemiol 1978;108:145-9.
24. Anonymous. Pneumococcal vaccines: WHO position paper. Wkly Epidemiol Rec 1999;74:177-83.
25. Fedson DS, Scott JAG. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 1999;17(Suppl): S11-18.
26. Mulholland K, Levine O, Nohynek H, Greenwood BM. Evaluation of vaccines for the prevention of pneumonia in children in developing countries. Epidemiol Rev 1999;21:43-55.
27. Clemens J, Brenner R, Rao M, Tafari N, Lowe C. Evaluating new vaccines for developing countries: efficacy or effectiveness? JAMA 1996;275:390-7.
28. Adegbola RA, Usen SO, Weber M, et al. Haemophilus influenzae type b meningitis in The Gambia after introduction of a conjugate vaccine. Lancet 1999;354:1091-2.
29. Nabors GS, Braun PA, Heise ML, et al. Sera from adults immunized with recombinant Rx1 PspA from Streptococcus pneumoniae cross-reacts with heterologous PspA molecules, and passively protects mice from fatal infection [Abstract]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September, 1999, p. 380.
30. Musher DM, Groover JE, Watson DA, Rodriguez-Barradas MC, Baughn RE. IgG responses to protein-conjugated pneumococcal capsular polysaccharides in persons who are genetically incapable of responding to unconjugated polysaccharides. Clin Infect Dis 1998;27:1487-90.